restriction spectrum imaging (RSI) for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Prostate Cancerrestriction spectrum imaging (RSI) - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial assesses whether a tailored MRI protocol that eliminates one or more aspects of current mpMRI technique is just as effective as the standard mpMRI protocol for cancer detection.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year

Year 1
The primary objective of this study is to compare the diagnostic accuracy of T2 weighted imaging (T2WI) and restriction spectrum imaging (RSI) (T2WI + RSI) to that of multiparametric MRI (mpMRI), for the detection of individual prostate cancer foci.

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

MRI technique
1 of 1

Experimental Treatment

302 Total Participants · 1 Treatment Group

Primary Treatment: restriction spectrum imaging (RSI) · No Placebo Group · Phase 2

MRI technique
Device
Experimental Group · 1 Intervention: restriction spectrum imaging (RSI) · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,077 Total Patients Enrolled
89 Trials studying Prostate Cancer
27,233 Patients Enrolled for Prostate Cancer
Aradhana VenkatesanPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are anticipated to undergo fusion guided biopsy at MD Anderson.